TerminatedEarly Phase 1

Topical Timolol 0.5% Solution for Proliferating Infantile Hemangiomas

United States6 participantsStarted 2010-03

Plain-language summary

The purpose of this study is to learn about a new potential use for topical timolol 0.5% aqueous solution that may help treat small uncomplicated infantile hemangiomas. This study would examine whether topical timolol could be a potential therapy.

Who can participate

Age range1 Month – 8 Months

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Exclusion criteria

✕. Subjects with facial, genital, perianal, hand, finger, feet, or toe IH
✕. Subjects with PHACES (plaque-like hemangioma on the face awaiting imaging) syndrome (proven) or suspected PHACES .
✕. Subjects with IH measuring more than 3cm in size or ulcerated.
✕. Children with a history of hypersensitivity to beta blockers.
✕. Children with a personal history of asthma.
✕. Children with known renal impairment.
✕. Children with known cardiac conditions that may predispose to heart block
✕. Personal history of hypoglycemia

What they're measuring

Proportion of Subjects in Treatment Group Compared to Placebo Group With at Least 75% Improvement in the Extent of the Hemangioma as Compared to Baseline Photos.

Timeframe: at 6 months

Trial details

NCT IDNCT01147601

SponsorOregon Health and Science University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2012-10

Results submitted2017-04-19

View on ClinicalTrials.gov More Hemangioma trials